Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: April 17, 2025
Subject: Regulatory approval of Blenrep (belantamab mafodotin) combinations for relapsed/refractory multiple myeloma by the UK Medicines and Healthcare products Regulatory Agency (MHRA).
Key Financial Metrics
This filing is a regulatory announcement regarding a specific product approval and does not contain financial statements. The text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes and Clinical Data
The primary material change is the first-in-world regulatory authorization of Blenrep combinations in the UK. This approval is supported by data from two Phase III trials (DREAMM-7 and DREAMM-8) showing superior efficacy versus standard of care:
- DREAMM-7 Trial (Blenrep + BVd vs. Daratumumab + BVd):
- Progression-Free Survival (PFS): Median PFS was 36.6 months for Blenrep vs. 13.4 months for comparator (Hazard Ratio [HR]: 0.41).
- Overall Survival (OS): 42% reduction in risk of death (HR: 0.58). Three-year OS rate was 74% (Blenrep) vs. 60% (comparator).
- DREAMM-8 Trial (Blenrep + BPd vs. Bortezomib + BPd):
- PFS: Median PFS not yet reached for Blenrep vs. 12.7 months for comparator.
- Safety Profile: Eye-related side effects were manageable with low discontinuation rates (≤9%). Common non-ocular adverse events included thrombocytopenia (87% in DREAMM-7) and neutropenia (63% in DREAMM-8).
Guidance, Outlook, and Risks
Regulatory Outlook:
- Global Status: Submissions are under review in 14 markets with additional approvals expected in 2025.
- United States: Prescription Drug User Fee Act (PDUFA) decision date set for July 23, 2025.
- Other Markets: Priority review granted in Japan, China (Breakthrough Therapy Designation), Canada, and Switzerland.
Management Commentary:
- GSK leadership describes the approval as a "transformative milestone" that could redefine treatment at or after first relapse.
- Blenrep is the only BCMA-targeted antibody-drug conjugate (ADC) in multiple myeloma, offering a differentiated mechanism of action.
Risks and Contingencies:
- Forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from projections.
- Specific risks are referenced in the "Risk Factors" section of GSK's 2024 Annual Report on Form 20-F.
Investor Verification Checklist
- Verify the PDUFA decision date of July 23, 2025, for US FDA approval.
- Monitor the status of regulatory reviews in the EU, Japan, and China for potential 2025 approvals.
- Review the "Risk Factors" in the 2024 Form 20-F for details on regulatory and commercialization risks.
- Assess the commercial impact of Blenrep as a first-in-class BCMA-targeted ADC in the relapsed/refractory multiple myeloma market.
- Confirm the safety management protocols for ocular adverse events in real-world settings.